Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.
Zhou F et al. Leuk Lymphoma. 2014 Jan 28. [Epub ahead of print].
Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
San Miguel JF. Haematologica. 2014 Jan;99(1):5-6. doi: 10.3324/haematol.2013.100982.
Management of bone disease in multiple myeloma.
Terpos E et al. Expert Rev Hematol. 2014 Jan 16. [Epub ahead of print].
Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation.
Wang XS et al. Clin Cancer Res. 2014 Jan 14. [Epub ahead of print].
Challenge test to bisphosphonates in patients with hypersensitivity reactions to drugs.
Minciullo PL et al. Allergol Immunopathol (Madr). 2014 Jan 7. pii: S0301-0546(13)00283-8. doi: 10.1016/j.aller.2013.09.010. [Epub ahead of print].
Spinal cord compression in multiple myeloma: A single center experience.
Jung HA et al. Leuk Lymphoma. 2014 Jan 8. [Epub ahead of print].
Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
Zhang J et al. Hematol Oncol. 2014 Jan 7. doi: 10.1002/hon.2126. [Epub ahead of print].
Carfilzomib-Associated Tumor Lysis Syndrome.
Shely RN et al. Pharmacotherapy. 2014 Jan 4. doi: 10.1002/phar.1397. [Epub ahead of print].
Collar Bone swellings–A Varied Presentation of Multiple Myeloma.
Justin Arockiaraj SV et al. Jpn J Clin Oncol. 2014 Jan;44(1):104. doi: 10.1093/jjco/hyt169.
Fear of impending fractures: when to refer? A case-based review.
Kronisch C et al. Clin Rheumatol. 2014 Jan 3. [Epub ahead of print].
Neurologic aspects of plasma cell disorders.
Sobol U et al. Handb Clin Neurol. 2014;120:1083-99. doi: 10.1016/B978-0-7020-4087-0.00073-5.
Myeloma-related Kidney Disease.
Leung N et al. Adv Chronic Kidney Dis. 2014 Jan;21(1):36-47. doi: 10.1053/j.ackd.2013.08.009.
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Dimopoulos MA et al. Ann Oncol. 2014 Jan;25(1):195-200. doi: 10.1093/annonc/mdt483.
